Surrozen, Inc. (NASDAQ:SRZN – Get Rating) was the recipient of a large decrease in short interest in December. As of December 15th, there was short interest totalling 97,000 shares, a decrease of 20.6% from the November 30th total of 122,100 shares. Approximately 0.5% of the shares of the company are short sold. Based on an average trading volume of 507,700 shares, the short-interest ratio is currently 0.2 days.
Institutional Investors Weigh In On Surrozen
A number of hedge funds and other institutional investors have recently bought and sold shares of SRZN. Bank of Montreal Can acquired a new stake in Surrozen during the 1st quarter valued at $377,000. FMR LLC bought a new position in Surrozen in the 2nd quarter valued at $744,000. Vanguard Group Inc. boosted its position in Surrozen by 3.2% in the 3rd quarter. Vanguard Group Inc. now owns 487,278 shares of the company's stock valued at $984,000 after buying an additional 15,299 shares during the last quarter. Finally, Board of Trustees of The Leland Stanford Junior University boosted its position in Surrozen by 3,102.9% in the 3rd quarter. Board of Trustees of The Leland Stanford Junior University now owns 781,960 shares of the company's stock valued at $1,580,000 after buying an additional 757,546 shares during the last quarter. 62.13% of the stock is owned by institutional investors and hedge funds.
Get Surrozen alerts:Surrozen Trading Down 8.1 %
Shares of SRZN traded down $0.05 during mid-day trading on Friday, reaching $0.58. The company had a trading volume of 848,891 shares, compared to its average volume of 1,863,713. Surrozen has a twelve month low of $0.34 and a twelve month high of $6.90. The company's 50-day moving average is $1.12 and its 200-day moving average is $2.17.
Surrozen (NASDAQ:SRZN – Get Rating) last issued its earnings results on Monday, November 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. On average, sell-side analysts predict that Surrozen will post -1.46 EPS for the current fiscal year.Analyst Upgrades and Downgrades
Several equities analysts have commented on SRZN shares. Bank of America cut Surrozen from a "neutral" rating to an "underperform" rating in a report on Wednesday, November 16th. Guggenheim cut Surrozen from a "buy" rating to a "neutral" rating in a report on Friday, November 18th. Finally, JPMorgan Chase & Co. cut Surrozen from a "neutral" rating to an "underweight" rating in a report on Tuesday, November 29th.
About Surrozen
(Get Rating)
Surrozen, Inc, a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Further Reading
- Get a free copy of the StockNews.com research report on Surrozen (SRZN)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.